It was an absolute pleasure to speak with Prof. Christopher Griffiths (University of Manchester, Manchester, UK) about recent developments in the treatment of psoriasis including the VOYAGE study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
- Could you tell us about the aims and design of the VOYAGE 1 study? (00:10-01:14)
- What has the study taught us about the efficacy and safety of guselkumab in psoriasis? (01:14-02:25)
- There are other novel IL-17/23 antagonists currently in development e.g. bimekizumab and mirikizumab, based on clinical data to date, which are you most excited/optimistic about? (02:25-03:42)
Disclosures: Christopher Griffiths has the following disclosures: AbbVie – (AD Board, Grant Holder), Almirall (Advisor), Amgen (Advisor), BMS (Speaker, Grant Holder) , Boehringer Ingelheim (Ad Board / Advisor), Celgene – (Ad Board / Speaker) , Galderma – (AD Board, Grant Holder) , Janssen – (Speaker, Grant holder) , LEO Pharma (Grant Holder / Speaker) , Lilly – (Grant Holder / Ad Board) , MSD (Advisor), Novartis (Ad Board / Speaker / Ad Board), Pfizer – (Grant Holder, Speaker) , Sandoz (Grant Holder) and UCB Pharma – (AD Board)
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Dermatological Conditions
Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prognosis, current treatment paradigm & pipeline therapies
The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!